Shionogi Inc. Announces FDA Approval Of CUVPOSA™ For The Treatment Of Chronic Severe Drooling In Pediatric Patients With Neurologic Conditions

Links shared publicly online about this topic.

  • 985
    total visits

Shionogi Inc. Announces FDA Approval Of CUVPOSA™ For The Treatment Of Chronic Severe Drooling In Pediatric Patients With Neurologic Conditions

medicalnewstoday.com

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patie

View full resource at medicalnewstoday.com

Tags: Neurology, Drug, Children's Health, FDA, Shionogi

  • Share

Most Recently Shared on July 30, 2010 at 6:04 pm By:

mnt_neurology MNT Neurology News

Shionogi Inc. Announces FDA Approval Of CUVPOSA™ For The Treatment Of Chronic Severe Drooling In Pediatric Patie... http://mnt.to/3GLX

2 years ago...

Also Shared By:

Neurology OW Neurology OW

MNT Pediatrics News MNT Pediatrics News

MNT Drug Approvals MNT Drug Approvals

MNT Pharma News MNT Pharma News

Shionogi launches CUVPOSA for pediatric chronic severe drooling

news-medical.net — “Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 2:09 pm By:

NewsMedical News-Medical.Net Health News

Shionogi launches CUVPOSA for pediatric chronic severe drooling: Shionogi Inc., the U.S.-based group company of ... http://bit.ly/gMBd6q

1 year ago...

Shionogi Announces FDA Approval Of KAPVAY™ - The First And Only Therapy Approved For Use With Stimulant Medication For The Treatment Of ADHD

medicalnewstoday.com — “Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of the non-stimulant medication KAPVAY™ (clonidine hydrochlorideView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on October 6, 2010 at 3:05 pm By:

mnt_adhd MNT ADHD & ADD News Health News

Shionogi Announces FDA Approval Of KAPVAY™ - The First And Only Therapy Approved For Use With Stimulant Medicati... http://mnt.to/3KPx

2 years ago...

Advertisement